Hemoglobin Testing Global Market Report 2024

The hemoglobin testing market has grown strongly in recent years. It will grow from $2.54 billion in 2023 to $2.71 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The expansion observed in the historical period can be attributed to factors such as the prevalence of anemia, maternal health initiatives, blood donation programs, the management of chronic diseases, and global health awareness campaigns.

The hemoglobin testing market is expected to see strong growth in the next few years. It will grow to $3.65 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. The anticipated growth in the forecast period can be attributed to factors such as rising healthcare investments, integration with chronic disease management, the expansion of point-of-care testing, an increasing focus on preventive healthcare, and preparedness for global health pandemics. Key trends expected in the forecast period encompass the adoption of telemedicine and remote monitoring, technological advancements, the development of home-based testing kits, integration with electronic health records (EHR), and a focus on non-invasive testing methods in the field of hemoglobin testing.

The hemoglobin testing market is poised for growth, driven by the increasing prevalence of chronic disorders such as diabetes. Diabetes, a chronic condition characterized by insufficient insulin production or utilization, necessitates regular monitoring through Hemoglobin A1c tests (HbA1c). These tests, recommended by the American Diabetes Association, play a crucial role in diabetes diagnosis. With over 34 million Americans having diabetes and an additional 88 million at risk, the demand for HbA1c testing devices is set to rise. Furthermore, global projections indicate a substantial increase in diabetes cases, reaching 783,700 individuals by 2045, emphasizing the pivotal role of hemoglobin A1c testing devices in managing chronic disorders.

The hemoglobin testing market is also anticipated to experience growth due to the rising cases of anemia. Anemia, characterized by a deficiency in red blood cells or hemoglobin, is a global concern. The need for early detection and routine testing has driven the demand for hemoglobin testing. In 2021, 1.92 billion individuals worldwide experienced anemia, with dietary iron deficiency being a leading cause. The emphasis on preventive healthcare and increased awareness further contributes to the robust growth of the hemoglobin testing market.

Major companies in the hemoglobin testing market are focusing on innovation, introducing products such as liquid chromatography analyzers to cater to larger customer bases. For example, Trivitron Healthcare launched NANO H5 and NANO H110, high-performance liquid chromatography analyzers designed for rapid HbA1c detection. These analyzers provide swift processing times, with NANO H110 offering dual test modes for HbA1c testing and Hb variant detection. Such innovations enhance laboratory turnaround time and accommodate varying workloads.

Advancements in technology, such as AI-based hemoglobin monitors, contribute to market growth. Companies such as Robert Bosch GmbH have introduced a portable Hemoglobin Monitor Solution (HMS) employing AI technology for non-invasive anemia screening. This solution, offering quick results within 30 seconds, particularly benefits resource-constrained environments. The integration of optical sensors and PPG signals ensures precise hemoglobin level measurements, presenting an innovative approach to hemoglobin monitoring.

In December 2021, F. Hoffmann-La Roche AG acquired TIB Molbiol Group, enhancing its capabilities in developing tests for new pathogens and health hazards. TIB Molbiol Group's expertise in blood screening aligns with F. Hoffmann-La Roche AG's commitment to advancing diagnostics, reinforcing their position in the hemoglobin testing market.

Major companies operating in the hemoglobin testing market report are Abbott Laboratories Inc., Bayer Medical Care Inc., Danaher Corporation, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche AG, Bio-Rad Laboratories Inc., Daiichi Sankyo Inc., ACON Laboratories Inc., DiaSys Diagnostic Systems GmbH, EKF Diagnostics Holdings PLC, Epinex Diagnostics Inc., Erba Diagnostics Inc., Alere Inc., ARKRAY Inc., Beckman Coulter Diagnostics Ltd., Diazyme Laboratories Inc., Masimo Corporation, Radiometer A/S, Sysmex Corporation, BioMedomics Inc., Germaine Laboratories Inc., Hemosure Inc., Humasis Co. Ltd., Immunostics Inc., LifeSign LLC, Medix Biochemica Oy AB, NanoenTek Inc., Nova Biomedical Corp., Quidel Corporation, TCS Biosciences Ltd., Siemens Healthcare GmbH, Mindray Medical International Limited, Nihon Kohden Corporation, Tosoh Corporation.

Asia-Pacific and North America were the largest region in the hemoglobin testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global hemoglobin testing market report during the forecast period. The regions covered in the hemoglobin testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hemoglobin testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of products in hemoglobin testing include reagents and consumables, as well as equipment. The reagents and consumables segment in the hemoglobin testing market encompasses various chemical reagents and consumable products utilized in the process of hemoglobin testing. Various technologies are employed for hemoglobin testing, including chromatography, immunoassay, spectrophotometry, and others. These testing products find application in diverse settings such as hospitals, clinics, laboratories, home care settings, blood banks, and others.

The hemoglobin testing market research report provides hemoglobin testing market statistics, including hemoglobin testing industry global market size, regional shares, competitors with a hemoglobin testing market share, detailed hemoglobin testing market segments, market trends and opportunities, and any further data you may need to thrive in the hemoglobin testing industry. This hemoglobin testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hemoglobin testing market consists of revenues earned by entities by providing services such as hemoglobin-cyanide, vanzetti's azide methemoglobin, reagent-less, non-invasive methods, and hemoglobin electrophoresis. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.